诺华公司的Kymriah：利用免疫系统的同时也伴随着控制成本的担忧。
Novartis's Kymriah: Harnessing Immune System Comes With Worry About Reining in Costs.
作者信息
Morrow Thomas
出版信息
Manag Care. 2017 Oct;26(10):28-30.
PMID:29068298
Abstract
FDA approval of the CAR T-cell therapy for leukemia could usher in an era of genetically engineered, individually tailored immunotherapies. But tap those brakes. Long-term results are in short supply-and there's that $475,000 price tag. Or is it a $750,000 price tag?
摘要
美国食品药品监督管理局（FDA）对治疗白血病的嵌合抗原受体（CAR）T细胞疗法的批准可能会开创一个基因工程、个性化定制免疫疗法的时代。但先别急。长期结果还很缺乏，而且还有那个47.5万美元的标价。或者是75万美元的标价？
Zotero 插件